Dare Bioscience, Inc. Lease, Cost
Dare Bioscience, Inc. (DARE) reported Lease, Cost of $667.58 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-13
- Dare Bioscience, Inc. lease, cost for the quarter ending 2026-06-30 was $667.58K, a 15.55% decline year-over-year.
- Dare Bioscience, Inc. lease, cost for the quarter ending 2026-03-31 was $687.97K, a 71.18% increase year-over-year.
- Dare Bioscience, Inc. lease, cost for the quarter ending 2025-12-31 was $784.08K, a 121.75% increase year-over-year.
- Dare Bioscience, Inc. lease, cost for the quarter ending 2025-09-30 was $699.00K, a 260.31% increase year-over-year.
- Dare Bioscience, Inc. lease, cost for fiscal 2025 was $2.58M, a 174.57% increase from fiscal 2024.
- Dare Bioscience, Inc. lease, cost for fiscal 2024 was $938.59K.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $667.58K 10-Q · filed 2026-08-13 | $1.36M 10-Q · filed 2026-08-13 | $2.14M derived: sum of 3 quarters · filed 2026-08-13 | $2.84M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $687.97K 10-Q · filed 2026-05-14 | $1.47M derived: sum of 2 quarters · filed 2026-05-14 | $2.17M derived: sum of 3 quarters · filed 2026-05-14 | $2.96M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $784.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.48M derived: sum of 2 quarters · filed 2026-03-26 | $2.27M derived: sum of 3 quarters · filed 2026-08-13 | $2.58M 10-K · filed 2026-03-26 | ||
| 2025-09-30 | $699.00K 10-Q · filed 2025-11-13 | $1.49M derived: sum of 2 quarters · filed 2026-08-13 | $1.79M 10-Q · filed 2025-11-13 | $2.24M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $790.48K 10-Q · filed 2026-08-13 | $729.00K 10-Q · filed 2025-08-14 | $1.19M 10-Q · filed 2026-08-13 | $1.10M 10-Q · filed 2025-08-14 | $1.55M derived: sum of 3 quarters · filed 2026-08-13 | $1.74M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $401.89K 10-Q · filed 2026-05-14 | $366.00K 10-Q · filed 2025-05-13 | $755.48K derived: sum of 2 quarters · filed 2026-05-14 | $949.48K derived: sum of 3 quarters · filed 2026-05-14 | $1.14M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $353.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $547.59K derived: sum of 2 quarters · filed 2026-03-26 | $738.59K derived: sum of 3 quarters · filed 2026-03-26 | $938.59K 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $194.00K 10-Q · filed 2025-11-13 | $385.00K derived: sum of 2 quarters · filed 2025-11-13 | $585.00K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $191.00K 10-Q · filed 2025-08-14 | $391.00K 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |